Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- CORPORATE ROUNDUP NEWS IN BRIEF
August 19, 2002
- MEDICAL DEVICE NEWS IN BRIEF
August 19, 2002
- To Further Concentrate on Ethical Drug Business: Takeda President
August 19, 2002
- FY2000 Nat'l Medical Costs Down 1.9% Due to Nursing Care Insurance
August 19, 2002
- DIAGNOSTIC NEWS IN BRIEF
August 19, 2002
- Kyowa Hakko to Start SMART Marketing Strategy in October
August 19, 2002
- Korosho Official Briefs on "General Manufacturing and Marketing Managers"
August 19, 2002
- WORLD NEW IN BRIEF
August 19, 2002
- Nikken to Transfer Chemical Business to Mitsui
August 19, 2002
- PFSB Negotiates Hike of Review Fees with Industry
August 19, 2002
- Daiichi, Suntory Hope for \20-30 Bil. Sales for New Company
August 19, 2002
- MCC to Review Disadvantages of Split-off Policy
August 19, 2002
- Record-high Life Expectancy Reported for Both Sexes in 2001
August 19, 2002
- FPMAJ to Present Industry's Proposal Regarding Application of New PAL
August 19, 2002
- Drugs to Be Included in 20th Quality Reevaluation Announced
August 19, 2002
- Fujisawa Invests US$8 Mil. in Sucampo
August 19, 2002
- REGULATORY NEWS IN BRIEF
August 19, 2002
- Tanabe to Establish JV with aaiPharma
August 19, 2002
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
August 19, 2002
- Gedeon Richter Sues 12 GE Houses for Famotidine Patent Infringement
August 19, 2002
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…